USING HAQ TO ESTIMATE HUI3 AND EQ-5D UTILITY VALUES IN SPANISH RHEUMATOID ARTHRITIS PATIENTS
Author(s)
Cristina Varela, Bsc, Pharmacoeconomic Manager1, Ignacio Fernández, MD, Pharmacoeconomic Specialist1, Miquel Layola, MD, Director of clinical studies2, Maria Dolores Ruiz, MD, Investigator of the Rheumatology Service3, Federico Navarro, Pr, Rheumatology Area Director31Roche Farma, Madrid, Spain; 2 IMS Health, Barcelona, Spain; 3 Hospital Universitario Virgen Macarena, Sevilla, Spain
OBJECTIVES: Description of HUI3 and EQ-5D utility values and their relation with HAQ score. METHODS: Observational, cross-sectional, naturalistic and multicentre study. A total of 244 patients aged 18 or more and with rheumatoid arthritis (RA) according to ACR diagnosis criteria were recruited by 14 Spanish rheumatologists over a 2-month period. Social (age, gender and race) and clinical variables (time of disease evolution, current affected joints and RA family history) were collected. Patients were also asked to fulfil three generic HRQoL questionnaires: Health Assessment Questionnaire (HAQ), Health Utility Index (HUI) and Euroqol (EQ-5D). Two linear regression models were used to predict HUI3 and EQ-5D utility values as functions of HAQ scores and age and gender. RESULTS: Mean age (SD) of patients was 57.8 (13.3) years, being 75.8% women and 96% Caucasians. Mean time of disease evolution (SD) was 10.8 (9) years. Patients’ distribution according to HAQ severity level groups was: 29% in level 1 (<0.5), 28% in level 2 (0.5
Conference/Value in Health Info
2008-11, ISPOR Europe 2008, Athens, Greece
Value in Health, Vol. 11, No. 6 (November 2008)
Code
PMS47
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Musculoskeletal Disorders